Cellebrite DI Positioned for Growth: Buy Rating Affirmed Amid Federal Demand Recovery and Strategic Alignments
I'm PortAI, I can summarize articles.
Cellebrite DI has received a Buy rating from Bank of America Securities, with a price target of $25.00, due to its growth potential and recovery in Federal demand. Analyst Tomer Zilberman highlighted the company's progress in the Federal segment and alignment with US administration priorities. Recent revenue growth has exceeded expectations, and the outlook for the fourth quarter remains strong. Additionally, the company's Cloud and SaaS solutions are thriving, and plans to reduce stock ownership from Sun Corp are seen positively. Needham also affirmed a Buy rating with a $24.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments